Abstract
Background: The study was designed to evaluate the impact of pharmacist-led clinical interventions on the health-related quality of life among tuberculosis patients in Pakistan.
Methods: A randomized, controlled prospective study was carried out in a Pakistan Institute of Medical Sciences hospital tuberculosis (TB) control center. Participants who visited the TB center between September 2020 and December 2021 were randomly assigned to two clusters, the usual care group (UC group) vs. the intervention group (pharmaceutical care group), in a 1:1 ratio by a simple envelope technique. In the intervention group, a patient received centered care that encompassed informed decision-making, which can increase the quality of care and monitoring of adverse drug events. However, the control group received routine TB treatment at the hospital. The EuroQol-5D-3L instrument was used to assess the health-related quality of life (HRQoL) at the baseline and in the third and sixth months of the treatment time period.
Results: A total of 503 patients were eligible, of which only 426 patients were included in this study. At the end of the study, n = 205 of the patients in the intervention group and n = 185 of those in the control group were analyzed. In the intervention group, the EQ-5D-3L health utility score improved significantly (p < 0.001) (from the baseline mean ± SD, 0.40 ± 0.36, to 6 months of treatment, 0.89 ± 0.09, while in the control group from 0.42 ± 0.35 to 0.78 ± 0.27). In multivariate regression analysis, the variables that remained statistically associated (p < 0.001) with the HRQoL (unstandardized β [95% confidence interval]) of the control group were as follows: gender, female vs. male (-0.039 [-0.076 to -0.003]); body weight, less than 40 kg vs. more than 40 kg (-0.109 [-0.195 to -0.024]); patients with any comorbidity vs. without comorbidity (-0.136 [-0.252 to -0.020]); and smokers vs. non-smokers (-0.204 [-0.291 to -0.118]). The study did not find any statistically significant associations between the intervention group’s variables and the HRQoL.
Conclusion: Patient-centered care interventions led by pharmacists as part of care coordination enhanced the HRQoL for TB patients significantly. According to this study, clinical pharmacists should be included in the interdisciplinary clinical staff for TB patient management.
Keywords: tuberculosis, patient-centered care, intervention, health-related quality of life, EQ-5D-3L
1 Background
Tuberculosis (TB), a severe, chronic lung disease, remains a major public health concern worldwide, particularly in low- and middle-income countries (Abiz et al., 2020; Khan et al., 2021). The World Health Organization (WHO) defines health as “full physical, psychological, and social welfare,” not just the absence of disease and disability (Saxena et al., 2001). The effect of TB on a patient’s health is considered essential because it can confront physical limitations and psychological, social, and economic constraints (Saleem et al., 2018). People who are suffering from TB have low self-esteem, a negative impression of their illness, and poor communication with their family and community members (Vecino et al., 2011; Iqbal et al., 2014). As a result, TB patients are challenged with physical problems, psychological stress, and economic issues (Zarova et al., 2018). More importantly, this lowers the health-related quality of life (HRQoL) of patients, which can also decrease the outcome of TB treatment (Jaber et al., 2016).
Pakistan ranks fifth among the 22 high TB-burdened countries (Aggarwal, 2019; Chen et al., 2021). In developing countries, particularly in Pakistan, very few studies have been carried out on the HRQoL of TB patients (Malik et al., 2018; Organization, 2021). Unfortunately, in most TB control programs, the quality of life of TB patients is neglected (Malik et al., 2018; Chen et al., 2021). Currently, TB control services are geared in the direction of enhancing the cure rate. Despite the fact that a positive cure rate is required, it does not alleviate TB patients’ physical, emotional, and social distress (WHO, 2020). In light of this, the WHO has realized that there needs to be better support for people with TB so that they can feel less distress, have a better quality of life, and get better results from their treatment. As a result, it advocates for “integrated patient-centered care and prevention.” This is very important for TB patients because it puts each patient’s rights, values, and needs at the center of TB control strategies (Jeremiah et al., 2022; Petersen et al., 2022). An ethical strategy for eliminating TB must be patient-centered and based on human rights. The social and personal conditions of the individual afflicted by TB must be given primary attention in addition to the urgent needs of medical therapy since TB patients encounter significant problems that go beyond the clinical aspects of the illness (Cocozza et al., 2020). According to recent findings, appropriately integrated patient-centered treatment can improve TB patients’ control (Kastien-Hilka et al., 2017a; Cocozza et al., 2020). Patient-centered care empowers patients to exercise their rights and fulfill their obligations while also improving their HRQoL through better knowledge of their health (Kastien-Hilka et al., 2017b; Yuen et al., 2021). However, little is known about whether the patient-centered care model would be helpful in improving the HRQoL of TB patients in Pakistan. The aim of this randomized, controlled trial was, thus, to assess whether pharmacist-led clinical interventions would improve the health-related quality of life of TB patients in Pakistan.
2 Methods
2.1 Study design
This randomized controlled prospective study was carried out in the tertiary-care hospital of the Pakistan Institute of Medical Sciences TB control center in Islamabad, Pakistan.
2.2 Study participant randomization
A single-blinded randomized controlled trial (RCT) was implemented, utilizing two parallel arms that were equally divided (in a 1:1 ratio using a simple envelope technique) between the intervention and control groups. The RCT has an intervention group, in which patients will be given pharmaceutical care + usual care, versus a usual care group, where participants will follow DOTS care according to the protocol of the TB control program and WHO (Organization, 2016). DOT by definition means observing TB patients to make sure they swallow each dose of anti-TB medication. This study is registered with Clinicaltrials.gov NCT04645836. The Standard Protocol Items: Recommendations for Interventional Trials guidelines were followed in this study. Participants who visited the TB center between September 2020 and December 2021 were included in this study. To search for the aspects that affect the HRQoL of TB patients, the data questionnaire was divided into two sections. The first section discusses trial variables based on a literature review, while the second section assesses the HRQoL using EQ-5D-3L and patient satisfaction with counseling using a pre-validated Urdu version questionnaire (Naqvi et al., 2019). A recruitment patient registration team referred interested participants for evaluating their eligibility and attaining informed consent. The process of randomization was conceded through a computer Research Randomizer, completed by the principal investigator. After that, the participants were randomly generated within sealed opaque envelopes. The envelopes were opened by the study participant allocation team. The pharmacist received all the pharmaceutical care group envelopes and counseled them in a private room at the TB control center, while DOTS supporters received usual care envelopes. The data collector’s team and the data analysis team that carried out outcome measurements, such as the quality of life and satisfaction with the intervention, remained fully blinded to the allocation of the control and intervention groups. The trial pharmacist was the primary contact person in case of possible problems during the trial. Still, even the contact person was entirely blinded to the preliminary outcome assessment to have fewer chances of bias.
2.2.1 Inclusion and exclusion criteria
The study’s participants also included those who were 18 years of age or older and were getting self-administered TB treatment. At the baseline, all patients who agreed to a pharmacist’s counseling session were enrolled in the trial. The pharmacists engaged in the research study must be registered with the Pakistan Pharmacy Council and have a valid Category A license granted by the Pharmacy Regulatory Authority of Pakistan. Patients under the age of 18, those with extrapulmonary TB, and those having difficulties in writing or speaking Urdu were excluded from the study. Furthermore, patients with incorrect contact information, transfer out, and lack of follow-up were excluded from the study analysis.
2.3 Pharmaceutical care intervention
In addition to their regular treatment, all patients in the intervention group received individualized patient care from a clinical pharmacist. A healthcare paradigm known as “centered care” puts the patient at the center of all decisions. This method takes patients’ individual needs, wants, and values into account while including them as active partners in their own care. Direct patient monitoring, lifestyle modification education, and counseling are among the services provided.
2.3.1 Patients’ pharmaceutical care and interventions
1) After the documentation of baseline data, patient care interventions were implemented. Pharmaceutical care was provided during follow-up visits to collect and prepare care plans for every TB patient. The intervention was divided both into non-pharmacological and pharmacological categories. Non-pharmacological treatments included information on appropriate drug use, while pharmacological interventions included medication addition or modification.
2) Both verbal and written methods of educating patients had been used. The booklet provides information on medication administration and lifestyle modification.
3) The pharmacist identified disease-related drug problems and made management recommendations during treatment.
4) Participants received a daily SMS text and weekly phone calls for anti-TB medicine intake and medication refill visit reminders.
2.3.1.1 Phases of interview
People in the intervention group were checked on at the start of the study, after 3 months, and after 6 months. The patient’s QoL was inspected at each follow-up visit. The first interview was conducted at the baseline before initiating the intensive phase of anti-tuberculosis treatment. The second interview was performed within 2 weeks of switching to the continuation phase, and the third interview was conducted at the end of 6 months. A separate room was set aside for patient counseling and interviews for the intervention group. The pharmacist in the intervention group had no access to or involvement in the care of the control group patients. To ensure a moral impression, all participants who visited the TB clinic after screening obtained an instructional booklet with information on preventative treatment for family members.
2.4 Usual care group
Both intervention and control groups received the clinic’s usual services, including education session and drug prescription by a physician, as necessary, and the phone contact number of the clinic. The hospital staff provided usual care to these groups; physicians, a nurse, and pharmacy technicians were all involved in the management. They were treated according to the hospital’s clinical standards, including assessment, medication management by hospital pharmacy technician staff, and a normal patient follow-up at the TB healthcare center. The pharmacist did not intervene on their behalf; however, these patients were given advice based on their needs, and they were not obligated to attend any pharmacist counseling sessions.
2.5 European quality of life scale (EQ-5D five-dimensional questionnaire)
The health-related quality of life is a phrase that characterizes a person’s overall life satisfaction and wellbeing concerning their health and medical treatment. The HRQoL takes into account multiple aspects that determine physical, emotional, and social health, including pain, mobility, emotions, and social connections. EQ-5D-3L, designed by the EuroQol group, is frequently used as an HRQoL questionnaire that provides a single health status index value and a basic description (Dion et al., 2004). EQ-5D-3L consists of a descriptive system, which includes a five-dimensional/question set of health mobility, self-care, usual activity, pain, and anxiety, in which each dimension can further be classified into three levels of severity responses: level 1, no problem; level 2, some problem; and level 3, extreme problem. The EQ-5D-3L questionnaire also includes a 20-cm health meter and a visual analog scale (VAS), on which the respondents’ current self-health state is recorded on two distinct end points of a graduated (0–100) scale, with 100 being the best imaginable health state and 0 being the worst imaginable health state. EuroQol offered the Urdu (national language of Pakistan) version of EQ-5D-3L, and the study was also registered with an EuroQol ID: 34816. The scores for each dimension can be added together to provide a health status; a score of 1 on each dimension (11111) indicates perfect health. By using country-specific value sets, each patient’s five health states can be summed up into a single health utility value. The EuroQol-specific value sets are not yet documented for the Pakistani general population. Therefore, EQ-5D-3L was scored using values from a general population survey conducted in the United Kingdom in 1995, which had previously been used in an early survey in Pakistan (Saleem et al., 2018; Shahid et al., 2018). Feedback from patients regarding pharmacist counseling was identified through a pre-validated Urdu version patient satisfaction feedback questionnaire.
2.6 Ethical considerations
The Ethical Research Board of the Pakistan Institute of Medical Sciences (PIMS) (F.1–1/2015/ERB/SZABMU/359) was also approved by Xi’an Jiaotong University (XJTU), Health Science Center Biology Scientific and Research Ethics Committee (2019–1257). The respondents were also asked to give their written and verbal consent to take part in this study.
2.7 Statistical analysis and sample size
For continuous data, mean standard deviation was used, whereas for categorical variables, data were presented in percentages and frequencies. The normality of the data distribution was checked using the Kolmogorov–Smirnov test. To test for statistical significance among patient variables, one-way ANOVA tests were used for the control and intervention comparison within the groups (EQ-5D-3L index score and EQ-VAS score). A p-value of less than 0.05 was considered significant. All the variables that were included in preliminary analyses of multivariates were examined to verify that the tolerance value variance inflation factor and homogeneity of variance were not violated. In multivariate analysis, independent variables having p < 0.2 in univariate analysis were included in the analysis. Statistical Package for Social Sciences (SPSS) version 26 software was used to analyze the data obtained. We assumed a 10% difference in the primary outcome (Mishra et al., 2017), an alpha of 0.05, and a power of 80%, thus requiring a minimum sample size of 385 patients for both groups. However, considering the potential for losses to follow-up to be 10%, the intended sample size was 213 subjects per group over a 6-month study time period; the final sample size was 426 patients for both groups.
3 Results
3.1 Patient enrolment
After they were found to be eligible, 426 of the 503 patients were randomly split into two groups: the intervention group with 213 patients and the control group with 213 patients. At the end of the study, n = 205 of the patients in the intervention group and n = 185 in the control group were included in the analysis. As indicated in Figure 1, the control group had 28 patients who dropped out, whereas the intervention group had eight patients who dropped out.
FIGURE 1.
Flowchart of the participants enrolled in the RCT (intervention and control groups).
3.2 Patient demographic characteristics
The age group of 31–50 years represented almost 40.2% of the participants in the study, followed by 18–30 years (30.5%) and >51 years (29.2%), with male patients dominating the study (54.3%). More than half of the participants (233, 59.7%) had no formal education, while the remaining participants had intermediate level education (67, 17.1%) and primary level education (73, 18.7%). Out of the total, 71, 18.2%, patients in the study were employed. More than half (69.4%) of them had urban residences. The majority of study participants (70.5%) were from low-income families. Diabetes (5.8%), hypertension (7.1%), and hepatitis C, co-infected with TB, were the most common comorbidities in the overall sample of 16.1% of patients, while 21.2% of patients were under 40 kg; the percentages of non-smokers and current smokers were 76.2% and 23.8%, respectively (Table 1).
TABLE 1.
Patients’ characteristics of the study groups, control vs. intervention.
| Variable | Intervention group, n = 205 (%) | Control group, n = 185 (%) | p-value |
|---|---|---|---|
| Age (years) | 0.51 | ||
| 18–30 | 65 (31.8) | 57 (30.8) | |
| 31–50 | 77 (37.6) | 77 (43.2) | |
| >51 | 63 (30.8) | 51 (27.6) | |
| Gender | 0.12 | ||
| Male | 123 (60) | 89 (48.1) | |
| Female | 82 (40) | 96 (51.9) | |
| Qualification | 0.31 | ||
| No education | 121 (59) | 112 (60.5) | |
| Primary level | 40 (19.5) | 33 (17.8) | |
| Intermediate level | 34 (16.6) | 33 (17.8) | |
| Master level | 4 (2.0) | 5 (2.7) | |
| Religious | 6 (2.9) | 2 (1.1) | |
| Education category | 0.31 | ||
| Illiterate | 121 (59) | 112 (39.5) | |
| Literate | 84 (41) | 73 (60.5) | |
| Employment status | 0.06 | ||
| Employed | 31 (15.1) | 40 (20.8) | |
| Unemployed | 174 (84.9) | 145 (78.4) | |
| Locality | 0.06 | ||
| Urban | 150 (73.2) | 121 (65.4) | |
| Rural | 55 (26.8) | 64 (34.6) | |
| Income | |||
| Low | 148 (72.2) | 130 (70.3) | 0.06 |
| Intermediate | 44 (21.5) | 51 (27.6) | |
| High | 13 (6.3) | 4 (2.2) | |
| Body weight | 0.07 | ||
| <40 kg | 37 (18) | 46 (24.9) | |
| ≥40 kg | 168 (82) | 139 (75.1) | |
| Type of comorbidities | 0.28 | ||
| Diabetes | 14 (6.8) | 9 (4.9) | |
| Hypertension | 13 (6.3) | 12 (6.5) | |
| Hepatitis | 5 (2.4) | 1 (0.5) | |
| Other | |||
| Comorbidities | 0.08 | ||
| No | 162 (83.9) | 165 (89.2) | |
| Yes | 33 (16.1) | 20 (10.8) | |
| Cigarette smoking | 0.22 | ||
| Smoker | 39 (19) | 42 (22.7) | |
| Non-smoker | 166 (81) | 143 (77.3) | |
| Reported to center | 0.09 | ||
| Delayed | 83 (40.5) | 97 (47.6) | |
| Not delayed | 122 (59.5) | 88 (52.4) |
Kilogram (kg).
3.3 The comparison of HRQoL scores among the usual and intervention groups
The patient’s QoL from usual care was evaluated from the first to the second follow-up (mean ± SD standard deviation, 0.42 ± 0.35 to 0.57 ± 0.29) and from the second to the third follow-up (0.57 ± 0.29 to 0.78 ± 0.27) (Table 2).
TABLE 2.
Comparison of HRQoL scores among the control and intervention groups.
| Group | Pharmaceutical care group (EQ-5D utility score, mean ± SD) | Usual care group (EQ-5D utility score, mean ± SD) | p-value |
|---|---|---|---|
| Month 0 baseline | 0.40 ± 0.36 | 0.42 ± 0.35 | 0.65 |
| After 3 months | 0.72 ± 0.25 | 0.57 ± 0.29 | 0.00 |
| After 6 months | 0.89 ± 0.09 | 0.78 ± 0.27 | 0.00 |
| EQ-VAS score | EQ-VAS score | ||
| Month 0 baseline | 45.3 ± 28.9 | 47.9 ± 28.1 | 0.36 |
| After 3 months | 71.7 ± 21.1 | 62.1 ± 25.4 | 0.00 |
| After 6 months | 85.5 ± 8.36 | 79.6 ± 16.6 | 0.00 |
There was no significant difference between both groups at the baseline. The result showed that after the intervention in the second and third follow-up visit, the intervention group had significantly higher mean scores than the control group of EQ-5D-3L utility. In the second follow-up visit in the pharmaceutical care group, patients’ EQ-5D utility score increased to mean ± SD 0.72 ± 0.25, while in control group participants, the EQ-5D utility score increased to 0.57 ± 0.29; there were statistically significant differences in the mean and standard deviation scores (p < 0.001). In the final follow-up visit, the pharmaceutical care group patients’ utility score mean (SD) increased to 0.89 ± 0.09, while in the usual care group, the score was 0.78 ± 0.27 (p < 0.001).
3.3.1 Health-related quality of life domain comparisons between the control and intervention group
When compared to the control group, the intervention group’s mean QOL domain scores improved significantly (p < 0.001). The worst affected domains were the psychological domain in both groups. After pharmacist counseling, in the intervention group, more improvement was seen in the psychological domain (p < 0.00). In the first follow-up visit, significant differences were present in the mobility mean and standard deviation score of the intervention group (1.46 and 0.54) and the control group (1.57 and 0.56) (p < 0.04). In the second follow-up visit, there was a significant difference between EQ-5D-3L utility scores of the intervention and control groups (p < 0.05). In the third follow-up assessment in three domains, self-care (p < 0.00), usual activities (p < 0.00), and psychological domain (p < 0.00), there were significant improvements in the intervention group compared to the UC group (Table 3).
TABLE 3.
Change of mean and standard deviation scores, and EQ-5D-3L and EQ-5D-VAS scores.
| First follow-up | Domain | Intervention group (mean ± SD) | Control group (mean ± SD) | p-value <0.05 |
|---|---|---|---|---|
| Mobility | 1.46 ± 0.54 | 1.57 ± 0.56 | 0.04 | |
| Self-care | 1.91 ± 0.72 | 1.86 ± 0.64 | 0.49 | |
| Usual activities | 1.86 ± 0.66 | 1.88 ± 0.64 | 0.84 | |
| Pain | 1.98 ± 0.64 | 1.93 ± 0.56 | 0.41 | |
| Anxiety/depression | 2.12 ± 0.76 | 2.03 ± 0.70 | 0.23 | |
| Second follow-up | ||||
| Mobility | 1.08 ± 0.27 | 1.23 ± 0.42 | 0.00 | |
| Self-care | 1.26 ± 0.54 | 1.85 ± 0.68 | 0.00 | |
| Usual activities | 1.45 ± 0.60 | 1.83 ± 0.65 | 0.00 | |
| Pain | 1.55 ± 0.63 | 1.70 ± 0.59 | 0.04 | |
| Anxiety/depression | 1.32 ± 0.53 | 1.76 ± 0.74 | 0.00 | |
| Third follow-up | ||||
| Mobility | 1.02 ± 0.16 | 1.02 ± 0.16 | 0.89 | |
| Self-care | 1.02 ± 0.16 | 1.49 ± 0.65 | 0.00 | |
| Usual activities | 1.16 ± 0.39 | 1.42 ± 0.54 | 0.00 | |
| Pain | 1.17 ± 0.39 | 1.22 ± 0.41 | 0.26 | |
| Anxiety/depression | 1.20 ± 0.40 | 1.54 ± 0.73 | 0.00 |
At the first follow-up visit, more than half the respondents reported moderate or severe difficulties with mobility, usual activities, pain, and anxiety/depression. In the control group, severe problems existed in self-care (14.6%), usual activities (15.7%), pain (13%), and anxiety (26.5%). By the second follow-up visit, 16.8% of patients reported extreme problems with anxiety and depression, 14.1% in usual care, 17.8% in self-care, and 6.5% in the pain category. At the third follow-up visit, no patients in the control group reported extreme mobility problems, while 14.6% reported problems with anxiety, 8.6% in self-care, and 2.7% reported extreme problems in usual activities (Figure 2).
FIGURE 2.
Change in the percentages of the quality of life in five domain scores of the intervention and control groups.
In the intervention group, extreme problems were experienced by TB patients in self-care (22.4%), usual activities (16.6%), pain (20%), and anxiety (36.1%). By the second follow-up visit, 8.8% reported extreme problems with pain, 5.9% in usual care, 4.9% in self-care, and 3.4% in the anxiety and depression category. At the third follow-up visit in the intervention group, no patients reported extreme problems; 1% of severe problems were identified in usual activities (Figure 2).
3.4 Regression analysis of the HRQoL by patients’ characteristics
A univariate logistic regression was used to quantitatively analyze the interactions of the study variables that had close associations with the TB-related HRQoL. A good fit model for the multivariate linear regression was determined (F = 8.66, p < 0.001, and adjusted R2 = 0.255). In the univariate logistic regression, the variables in control group participants that were associated with the HRQoL included the following: age groups, 31–50 vs. 18–30 (unstandardized β [95% CI]; p-value) (0.27 [-0.013 to 0.067]; p = 0.18) and >51 vs. 18–30 years -0.03 [-0.060 to 0.001]; p = 0.04); gender, female vs. male (-0.04 [-0.080 to -0.001]; p = 0.04); there was a significant difference in the study outcome between patients with a body weight less than 40 kg compared to those with body weight greater than 40 kg (-0.185 [-0.273 to -0.097]; p = 0.00), with a comorbid condition vs. without a comorbid condition (-0.212 [-0.336 to -0.087]; p = 0.00), cigarette smokers vs. cigarette non-smokers (-0.226 [-0.315 to -0.137]; p = 0.00), and with the those reported to the center within 30 days vs. those reported after more than 30 days (0.124 [ 0.080 to 0.168]; p = 0.00) (Table 4).
TABLE 4.
Difference in the HRQoL through patients’ characteristics of the intervention group using the univariate linear regression.
| Variable | Control group EQ-5D-3L index (univariate linear regression) | Intervention group EQ-5D-3L index (univariate linear regression) | ||
|---|---|---|---|---|
| Unstandardized β [95% CI] | p-value | Unstandardized β [95% CI] | p-value | |
| Age (years) | ||||
| 31–50 vs. 18–30 | 0.27 [-0.013 to 0.067] | 0.18 | 0.006 [-0.007 to 0.020] | 0.36 |
| >51 vs. 18–30 | - 0.03 [-0.060 to 0.001] | 0.04 | -0.017 [-0.016 to 0.003] | 0.15 |
| Gender | ||||
| Female vs. male | -0.04 [-0.080 to -0.001] | 0.04 | 0.007 [-0.007 to 0.020] | 0.32 |
| Qualification | ||||
| Literate vs. illiterate | -0.019 [-0.059 to 0.022] | 0.36 | -0.002 [-0.011 to 0.016] | 0.72 |
| Employment status | ||||
| Unemployed vs. employed | 0.018 [-0.067 to 0.030] | 0.45 | -0.006 [-0.025 to -0.012] | 0.50 |
| Locality | ||||
| Urban vs. rural | -0.035 [-0.119 to 0.048] | 0.40 | -0.617 [-1.197 to -0.037] | 0.03 |
| Income | ||||
| Low vs. high | 0.011 [-0.076 to 0.098] | 0.80 | 0.021 [ -0.008 to 0.050] | 0.15 |
| Intermediate vs. high | -0.012 [-0.057 to 0.032] | 0.58 | 0.001 [ -0.016 to 0.017] | 0.95 |
| Body weight | ||||
| <40 kg vs. ≥40 kg | -0.185 [-0.273 to -0.097] | 0.00 | 0.021 [-0.013 to 0.056] | 0.18 |
| Comorbidities | ||||
| Yes vs. no | -0.212 [-0.336 to -0.087] | 0.00 | -0.028 [-0.064 to 0.007] | 0.12 |
| Cigarette smoker | ||||
| Smoker vs. non-smoker | -0.226 [-0.315 to -0.137] | 0.00 | -0.007 [-0.040 to 0.0.027] | 0.69 |
| Reported center | ||||
| Not delayed vs. delayed | 0.124 [ 0.080 to 0.168] | 0.00 | 0.002 [-0.025 to 0.029] | 0.87 |
Univariate analysis for significant variations with p < 0.2 in the HRQoL was included in multivariate regression analyses.
In multivariate regression analysis, the factors that remained statistically associated (unstandardized β [95% confidence interval]; p-value) with the control group were as follows: gender, female vs. male (-0.039 [-0.076 to -0.003]; p = 0.03); body weight less than 40 kg vs. more than 40 kg (-0.109 [-0.195 to -0.024]; p = 0.01); patients with any comorbidity vs. without comorbidity (-0.136 [-0.252 to -0.020]; p = 0.02); and smokers vs. non-smokers (-0.204 [-0.291 to -0.118]; p = 0.00) (Table 5).
TABLE 5.
Difference in the HRQoL through patients’ characteristics of the control group using multiple linear regression coefficients.
| Variable | Control group EQ-5D-3L index (multivariable linear regression model) | Intervention group EQ-5D-3L index (multivariable linear regression model) | ||
|---|---|---|---|---|
| Unstandardized β [95% CI] | p-value | Unstandardized β [95% CI] | p-value | |
| Age (years) | ||||
| 18–30 vs. >51 | 0.009 [-0.033 to -0.051] | 0.66 | Not applied | ----- |
| 31–50 vs. >51 | -0.015 [-0.046 to 0.016] | 0.32 | -0.007 [-0.016 to 0.002] | 0.14 |
| Gender | ||||
| Male vs. female | -0.039 [-0.076 to -0.003] | 0.03 | Not applied | ----- |
| Qualification | ||||
| Illiterate vs. literate | Not applied | ----- | Not applied | ----- |
| Employment status | ||||
| Employed vs. unemployed | Not applied | ----- | Not applied | |
| Locality | ||||
| Rural vs. urban | Not applied | ----- | -0.031 [-0.060 to -0.001] | 0.08 |
| Income | ||||
| Low vs. high | Not applied | ----- | 0.018 [-0.011 to 0.048] | 0.21 |
| Intermediate vs. high | Not applied | |||
| Body weight | ||||
| <40 kg vs. ≥40 kg | -0.109 [-0.195 to -0.024] | 0.01 | 0.015 [-0.019 to 0.049] | 0.39 |
| Comorbidities | ||||
| Yes vs. no | -0.136 [-0.252 to -0.020] | 0.02 | -0.024 [-0.060 to 0.011] | 0.17 |
| Cigarette smoker | ||||
| Smoker vs. non-smoker | -0.204 [-0.291 to -0.118] | 0.00 | Not applied | ----- |
| Reported center | ||||
| Delayed vs. not Delayed | -0.032 [-0.068 to -0.005] | 0.09 | Not applied | ----- |
CI (confidence interval), univariate analysis with p < 0.2 is considered for the fit model multivariate linear regression for the control group analysis with F = 8.66, p < 0.001, and adjusted R2 = 0.255, and for the intervention group model with F = 2.30, p < 0.04, and adjusted R2 = 0.055. Collinearity (variance inflation factor = 10) and tolerance value < 0.1.
In the univariate logistic regression (Table 4), the variables of the intervention group participants that were associated with the HRQoL included the following: age group >51 vs. 18–30 (-0.017 [-0.016 to 0.003]; p = 0.15), residency urban vs. rural (-0.617 [-1.197 to -0.037]; p = 0.03), income status of the intervention group participants (0.021 [-0.008 to 0.050]; p = 0.15), body weight less than 40 kg vs. more than 40 kg (0.021 [-0.013 to 0.056]; p = 0.18), and patients with any comorbidity vs. without comorbidity (-0.028 [-0.064 to 0.007]; p = 0.12). A good fit model for the multivariate linear regression was determined (F = 2.30, p < 0.04, and adjusted R2 = 0.055), while in multivariate regression analysis, the factors were not statistically associated with the HRQoL (Table 5).
3.5 Patient satisfaction
The majority of respondents (92.2%) stated that they were able to obtain advice from a pharmacist without difficulty. A total of 78.1% of patients agreed that they had gained TB-related knowledge based on their requirements. The majority of patients in the intervention group (83.7%) expressed satisfaction with regards to their concerns about medication. A majority of them (97.5%) seemed willing to recommend pharmacists’ counseling to others and suggested that this program be offered in pharmacies throughout the localities in the country. Moreover, 63.9% of patients have said they are prepared to pay for counseling in the future (Table 6).
TABLE 6.
Feedback from patients regarding pharmacist counseling.
| Patient satisfaction feedback regarding pharmacist counseling | Response | n (%) |
|---|---|---|
| Were you able to get counseling without any difficulty? | Yes | 189 (92.2) |
| No | 16 (7.8) | |
| Were you able to obtain the knowledge you required? | Yes completely | 160 (78.1) |
| Yes, to some extent | 25 (12.1) | |
| No, I did not get | 20 (9.8) | |
| Did you find the pharmacist helpful in resolving your questions? | Very helpful | 171 (83.4) |
| Somewhat helpful | 24 (11.7) | |
| Not helpful | 10 (4.8) | |
| What is your opinion about the time duration of pharmacist counseling? | More time should be given | 60 (29.2) |
| Appropriate time was given | 139 (67.8) | |
| My time was wasted | 6 (2.9) | |
| Will you recommend getting counseling from pharmacists to others? | Yes | 200 (97.5) |
| No | 5 (2.5) | |
| In your opinion, should this service be offered by pharmacies in your locality? | Yes | 205 (100) |
| No | 0 (0) | |
| Are you willing to pay for this counseling service? | Yes | 131 (63.9) |
| No | 74 (36.1) | |
| How would you rate your satisfaction with pharmacist counseling? | Very satisfied | 147 (71.7) |
| Satisfied | 40 (19.5) | |
| Uncertain | 13 (6.3) | |
| Not satisfied | 5 (2.4) |
4 Discussion
Since health is a basic human right and a crucial global societal objective that is essential for human needs, it is important to improve the HRQoL, even in disease conditions (Pinto et al., 2017). TB management is very complicated that involves several drugs and a lengthy duration of treatment. These aspects have a substantial impact on the patients’ quality of life (Qiu et al., 2020). The EQ-5D-3L questionnaire was used in this RCT to assess the HRQoL and its important determinants in TB patients. To the best of our knowledge, this is the first RCT for evaluating the improvements in the HRQoL in TB patients from a low-income country, Pakistan. The involvement of a clinical pharmacist service in standard treatment resulted in an enhanced HRQoL in 6-month follow-up visits. EQ-5D-3L (mean 0.40–0.89) and EQ-VAS (mean 45.3–85.4) improved with the intervention provided by the pharmacist. Findings similar to our study were reported in previous studies (Mishra et al., 2017; Saleem et al., 2018; Ali et al., 2019; Munsour et al., 2020). According to the research study, the quality of life of the intervention group increased much more, following educational counseling (Awaisu et al., 2012; Howyida et al., 2012; Kh et al., 2014). One of the main reasons for this improvement in the HRQoL was the patient-centered care that may have helped patients get rid of their symptoms and improve their ability to accept anti-TB treatment. The present study’s findings supported a similar argument that empowering patients through centered care positively affects the HRQoL (Khachadourian et al., 2020). These findings recognize the significant role that a pharmacist performs as a member of a multidisciplinary team in improving the quality of life and medical services of TB patients.
Consistent with prior research studies (Bauer et al., 2015; Kisaka et al., 2016), our findings suggest that EQ-5D and EQ-VAS scores significantly increase as the treatment progresses. According to earlier research (Dujaili et al., 2015; Singh et al., 2017), the greatest improvement in EQ-5D scores was seen in the first 2 months and 6 months after treatment. In this study, the baseline EQ-5D utility score of TB patients was similar to the previous study conducted by Saleem et al. (2018) and was lower than 0.70 according to the study by Awaisu et al. (2012), showing differences in absolute values between studies (Awaisu et al., 2012; Saleem et al., 2018). The results of EQ-5D index scores vary depending on the value set (“tariff”) because each population may show different preferences for various health conditions (Van Hout et al., 2012). Unfortunately, research studies on the EQ-5D-3L utility score for TB patients are still rare; consequently, the findings of this study on utility scores across different health statuses might serve as a reference for such analyses. In this study, the highest increase in EQ-5D scores was recorded within the first 2 months of treatment; this result is similar to that previously reported by Dujaili et al. (2015) and Saleem et al. (2018). Physical, mental, and social problems are common among TB patients, due to prolonged therapy and the infectious nature of the disease (Zarova et al., 2018; Aggarwal, 2019). This finding is consistent with previous research studies (Singh et al., 2017; Aggarwal, 2019). The psychological domain has reported more problems than the physical, self-care, and pain categories; in addition, the results are consistent with those of a past study (Sartika et al., 2019). At the initiation of treatment, anxiety and depression were found in 36.1% of intervention group patients and 26.5% of the control group patients. The point of concern is that 14.6% still indicated anxiety and depression at the end of treatment in the control group. This is comparable to previous studies conducted in Pakistan, which reported that 46% and 55.5% of TB patients have anxiety and/or depression after treatment, respectively (Husain et al., 2008; Saleem et al., 2018). Another study reported that the reasons for the low HRQoL even after treatment were the long treatment period, isolation from their family, and low socioeconomic status (Sulehri et al., 2010). This finding highlights the critical importance of assessing TB patients’ mental health and providing appropriate counseling to those who require it the most.
Similar to other research studies, in this study, we also sought to understand the factors that explained the difference in the quality of life scales (Eq.(5D)–(3L)) (Louw et al., 2016; Banerjee et al., 2019). Educating people may result in a better ability to cope with TB infections and an increase in the awareness about illness control and prevention, which will increase the HRQoL (Wu et al., 2009; Chizimba, 2012). Memory problems, anxiety and depression, and economic difficulties all are identified as contributing factors to a lower HRQoL (Chen et al., 2021; Febi et al., 2021). Based on the analysis, male patients with TB had an improved HRQoL compared to female patients, and these findings are comparable with previous research studies (Samuel et al., 2022). Female patients are the most neglected population in society, possibly due to the high levels of stigma and discrimination against them in Pakistan (Habib et al., 2021). As a result, gender is an important social predictor of health, and inequalities in gender-related HRQoL parameters must be considered (Izhar et al., 2021). In this study, in the control group, smoking was identified to interact with the trend of the HRQoL of TB patients. Just as the previous studies proposed, smoking suppresses the immune system, resulting in higher bacillary loads, which can aggravate disease symptoms and decrease physical health improvement with treatment (Banerjee et al., 2019; Magis-Escurra et al., 2021). The study results propose that comorbidity illnesses significantly affect the HRQoL. The relative reduction in the QoL among those with comorbidities is similar to the previous studies (Johansson et al., 2013; Butterly et al., 2023).
The present study’s findings supported similar arguments that empowering patients through centered care positively affects the HRQoL (Khachadourian et al., 2020). These findings recognize the significant role that a pharmacist performs as a member of a multidisciplinary team in improving the quality of life and medical services of TB patients. The HRQoL of TB patients improved significantly in the intervention group. This shows the involvement of the clinical pharmacist in TB care, leading to positive effects in patient care and the HRQoL across all five domains in all patients in the intervention group. The findings of this study are similar to those of the previous studies (Munsour et al., 2020; Abubakar and Atif, 2021). This shows that a pharmacist’s involvement in TB care increases patients’ HRQoL across all five domains in all patients in the intervention group. Most patients found counseling easy and acknowledged the pharmacist’s support; they were satisfied with the answers they received and sought out more counseling opportunities. Our findings are in line with those of other studies (AlQarni et al., 2019; Naqvi et al., 2019). A significant proportion of participants were willing to pay for the service, and the level of satisfaction is consistent with the findings from studies conducted in Pakistan and Saudi Arabia (AlShayban et al., 2020; Khan et al., 2022). Pharmacists should provide patients with precise, clear, and relevant information about their medications. The findings of this study point to the importance of clinical pharmacist services in the TB health sector in Pakistan.
4.1 Limitations
This study’s notable advantage was that it was the first randomized controlled trial to examine how EQ-5D-3L scores of individuals changed in Pakistan, a country where TB is prevalent. Moreover, treatment and consultation were provided free of charge to our study patients. This interventional study outcome will help in establishing the significance of fulfilling a pharmacist-led educational intervention in TB care settings to improve patients’ self-care practices and treatment outcomes. There are, however, several limitations to this study that should be noted. First, there is the probability of a selection bias among TB participants since in this study only those participants who were willing to take part and the study condition of fluency in the national language Urdu limited the range of possible participants. A significant number of patients who visit the medical facility are from diverse towns and are only able to communicate effectively in their local language. Therefore, they have been unable to participate in the study. All participants were ensured that their refusal to be involved in the study would have no impact on their routine treatment so that they would not feel forced to play a part in the trial. Second, we applied an EQ-5D-3L health utility value based on the UK general population, although it has been conducted previously in Pakistan (Saleem et al., 2018; Habib et al., 2021). To provide a more accurate evaluation of the HRQoL in future research studies, a health utility value based on the general population of Pakistan should be established.
4.2 Policy implications
It is necessary to include the patient perspective when prescribing anti-TB medications. When patients are involved in treatment, they become vital participants in the control and eradication of TB (Organization, 2014). A patient-centered strategy will increase their social support and advocacy about the disease and treatment, which will help in improving patient satisfaction, HRQoL, and treatment outcomes, benefiting both the patients and society. Even though the present exercise is limited in low- and middle-income countries, this approach needs to be adopted. Therefore, the policymakers should initiate its implementation and documentation on a priority basis.
5 Conclusion
This study appears to be the first RCT in Pakistan addressing the HRQoL of TB and enhancing a pharmacist’s role in patient-centered care in collaboration with the TB control team. Patient-centered care interventions led by pharmacists, as a part of care coordination, enhanced the HRQoL for TB patients significantly. Most prominently, these findings show that the addition of pharmacists as group members in providing patient-centered care in low-income countries can positively support the TB-related HRQoL. Low-income countries should follow the patient-centered care approach. The findings of this study point toward the importance of clinical pharmacist services in the TB health sector in developing countries.
Acknowledgments
The authors would like to acknowledge the study and clinical staff who contributed to or are involved in this project. They are very thankful to Asad, Nemati, and Saira Khan from the Pakistan Institute of Medical Sciences, Islamabad, for their support and research assistants from Quaid-i-Azam University, Islamabad, and TB Control Center, Pakistan, who supported their data collection and demonstrated consistent attention to detail and strong organizational skills throughout the data collection processes.
Funding Statement
This work was funded by the “Young Talent Support Plan;” the “High Achiever Plan” of the Health Science Center, Xi’an Jiaotong University; and the Central University Basic Research Fund (2015qngz05).
Data availability statement
The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by the Pakistan Institute of Medical Sciences hospital, Islamabad, and the Shaheed Zulfiqar Ali Medical University, Islamabad (F.1–1/2015/ERB/SZABMU/359), and were ethically approved after scientific reviews. The study was also approved by Xi’an Jiaotong University, Health Science Center Biology Scientific and Research Ethics Committee (2019–1257). It was also registered at ClinicalTrials.gov (NCT04645836). The patients/participants provided their written informed consent to participate in this study.
Author contributions
FarK and YF participated in the conceptualization and methodology of the study. Design and preparation of the study protocol was carried out by FarK, FaiK, KH, AR, and JC. FarK and MA carried out data extraction and analysis. FarK wrote the original manuscript. KH, AR, and MA edited the manuscript. YF carried out funding resource acquisition and supervision. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
- Abiz M., Robabi H., Salar A., Saeedinezhad F. (2020). The effect of self-care education on the quality of life in patients with pulmonary tuberculosis. Med. Surg. Nurs. J. 9, 7–9. 10.5812/msnj.108877 [DOI] [Google Scholar]
- Abubakar M., Atif M. (2021). Impact of pharmacist-led interventions on diabetes management at a community pharmacy in Pakistan: A randomized controlled trial. Inq. J. Health Care Organ. Provis. Financing 58, 00469580211036283. 10.1177/00469580211036283 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Aggarwal A. N. (2019). Quality of life with tuberculosis. J. Clin. Tuberc. other Mycobact. Dis. 17, 100121. 10.1016/j.jctube.2019.100121 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ali S., Ali M., Paudyal V., Rasheed F., Ullah S., Haque S., et al. (2019). A randomized controlled trial to assess the impact of clinical pharmacy interventions on treatment outcomes, health related quality of life and medication adherence among hepatitis C patients. Patient Prefer. adherence 13, 2089–2100. 10.2147/PPA.S224937 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Alqarni K., Alqarni E. A., Naqvi A. A., Alshayban D. M., Ghori S. A., Haseeb A., et al. (2019). Assessment of medication adherence in Saudi patients with Type II diabetes mellitus in Khobar City, Saudi Arabia. Front. Pharmacol. 10, 1306. 10.3389/fphar.2019.01306 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Alshayban D. M., Naqvi A. A., Islam M., Almaskeen M., Almulla A., Alali M., et al. (2020). Patient satisfaction and their willingness to pay for a pharmacist counseling session in hospital and community pharmacies in saudi healthcare settings. Front. Pharmacol. 11, 138. 10.3389/fphar.2020.00138 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Awaisu A., Haniki Nik Mohamed M., Noordin N. M., Muttalif A. R., Aziz N. A., Syed Sulaiman S. A., et al. (2012). Impact of connecting tuberculosis directly observed therapy short-course with smoking cessation on health-related quality of life. Tob. Induc. Dis. 10, 2–9. 10.1186/1617-9625-10-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Banerjee S., Bandyopadhyay K., Taraphdar P., Dasgupta A. (2019). Effect of DOTS on quality of life among tuberculosis patients: A follow-up study in a health district of Kolkata. J. Fam. Med. Prim. Care 8, 1070–1075. 10.4103/jfmpc.jfmpc_347_18 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bauer M., Ahmed S., Benedetti A., Greenaway C., Lalli M., Leavens A., et al. (2015). Health-related quality of life and tuberculosis: A longitudinal cohort study. Health Qual. life outcomes 13, 65–13. 10.1186/s12955-015-0250-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Butterly E. W., Hanlon P., Shah A. S., Hannigan L. J., Mcintosh E., Lewsey J., et al. (2023). Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: An individual participant data meta-analysis. Plos Med. 20, e1004154. 10.1371/journal.pmed.1004154 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen X., Xu J., Chen Y., Wu R., Ji H., Pan Y., et al. (2021). The relationship among social support, experienced stigma, psychological distress, and quality of life among tuberculosis patients in China. Sci. Rep. 11, 24236–24311. 10.1038/s41598-021-03811-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chizimba R. M. (2012). Relationship between knowledge, risk perceptions and socio-demographic factors and TB diagnosis in Ntcheu district in Malawi. Citeseer. [Google Scholar]
- Cocozza A., Linh N., Nathavitharana R., Ahmad U., Jaramillo E., Gargioni G., et al. (2020). An assessment of current tuberculosis patient care and support policies in high-burden countries. Int. J. Tuberc. Lung Dis. 24, 36–42. 10.5588/ijtld.19.0183 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dion M.-J., Tousignant P., Bourbeau J., Menzies D., Schwartzman K. (2004). Feasibility and reliability of health-related quality of life measurements among tuberculosis patients. Qual. life Res. 13, 653–665. 10.1023/B:QURE.0000021320.89524.64 [DOI] [PubMed] [Google Scholar]
- Dujaili J. A., Sulaiman S. A. S., Hassali M. A., Awaisu A., Blebil A. Q., Bredle J. M. (2015). Health-related quality of life as a predictor of tuberculosis treatment outcomes in Iraq. Int. J. Infect. Dis. 31, 4–8. 10.1016/j.ijid.2014.12.004 [DOI] [PubMed] [Google Scholar]
- Febi A. R., Manu M. K., Mohapatra A. K., Praharaj S. K., Guddattu V. (2021). Psychological stress and health-related quality of life among tuberculosis patients: A prospective cohort study. ERJ open Res. 7, 00251–02021. 10.1183/23120541.00251-2021 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Habib S. S., Jamal W. Z., Zaidi S. M. A., Siddiqui J.-U.-R., Khan H. M., Creswell J., et al. (2021). Barriers to access of healthcare services for rural women—applying gender lens on TB in a rural district of sindh, Pakistan. Int. J. Environ. Res. Public Health 18, 10102. 10.3390/ijerph181910102 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Howyida S., Heba A., Abeer Y. (2012). Effect of counseling on self-care management among adult patients with pulmonary tuberculosis. Life Sci. J. 9, 956–964. [Google Scholar]
- Husain M. O., Dearman S. P., Chaudhry I. B., Rizvi N., Waheed W. (2008). The relationship between anxiety, depression and illness perception in tberculosis patients in Pakistan. Clin. Pract. Epidemiol. Ment. health 4, 4–5. 10.1186/1745-0179-4-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Iqbal M., Iqbal M., Bahari M., Iqbal M. (2014). Health-related quality of life among tuberculosis patients in Pakistan: A cross sectional study using WHOQOL-BREF. Value Health 17, A601–A602. 10.1016/j.jval.2014.08.2086 [DOI] [PubMed] [Google Scholar]
- Izhar M. D., Butar M. B., Hidayati F., Ruwayda R. (2021). Predictors and health-related quality of life with short form-36 for multidrug-resistant tuberculosis patients in jambi, Indonesia: A case-control study. Clin. Epidemiol. Glob. Health 12, 100872. 10.1016/j.cegh.2021.100872 [DOI] [Google Scholar]
- Jaber A. A. S., Khan A. H., Syed Sulaiman S. A., Ahmad N., Anaam M. S. (2016). Evaluation of health-related quality of life among tuberculosis patients in two cities in Yemen. PloS one 11, e0156258. 10.1371/journal.pone.0156258 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jeremiah C., Petersen E., Nantanda R., Mungai B. N., Migliori G. B., Amanullah F., et al. (2022). The WHO Global Tuberculosis 2021 Report–not so good news and turning the tide back to End TB. Int. J. Infect. Dis. 124, S26–S29. 10.1016/j.ijid.2022.03.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Johansson R., Carlbring P., Paxling B., Andersson G. (2013). Depression, anxiety and their comorbidity in the Swedish general population: Point prevalence and the effect on health-related quality of life. PeerJ 1, e98. 10.7717/peerj.98 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kastien-Hilka T., Rosenkranz B., Schwenkglenks M., Bennett B. M., Sinanovic E. (2017a). Association between health-related quality of life and medication adherence in pulmonary tuberculosis in South Africa. Front. Pharmacol. 8, 919. 10.3389/fphar.2017.00919 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kastien-Hilka T., Rosenkranz B., Sinanovic E., Bennett B., Schwenkglenks M. (2017b). Health-related quality of life in South African patients with pulmonary tuberculosis. PloS one 12, e0174605. 10.1371/journal.pone.0174605 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kh J., Zareban I., Alizadeh-Siuki H., Izadirad H. (2014). The impact of educational intervention based on health belief model on promoting self-care behaviors in patients with smear-positive pulmonary TB. J. Health Educ. Health Promot. Summer 2, 143–152. [Google Scholar]
- Khachadourian V., Truzyan N., Harutyunyan A., Petrosyan V., Davtyan H., Davtyan K., et al. (2020). People–centred care versus clinic–based DOT for continuation phase TB treatment in Armenia: A cluster randomized trial. BMC Pulm. Med. 20, 105–110. 10.1186/s12890-020-1141-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- Khan F., Khan A., Khan F., Hayat K., Rehman Au C. J., Khalid W., et al. (2022). Assessment of adverse drug events, their risk factors, and management among patients treated for multidrug-resistant TB: A prospective cohort study from Pakistan. Front. Pharmacol. 13, 876955. 10.3389/fphar.2022.876955 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Khan F. U., Khan F. U., Hayat K., Chang J., Kamran M., Khan A., et al. (2021). Impact of protracted displacement on delay in the diagnosis associated with treatment outcomes: A cross-sectional study in internally displaced tuberculosis patients of Pakistan. Int. J. Environ. Res. Public Health 18, 11984. 10.3390/ijerph182211984 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kisaka S., Rutebemberwa E., Kasasa S., Ocen F., Nankya-Mutyoba J. (2016). Does health-related quality of life among adults with pulmonary tuberculosis improve across the treatment period? A hospital-based cross sectional study in mbale region, eastern Uganda. BMC Res. notes 9, 467–510. 10.1186/s13104-016-2277-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- Louw J. S., Mabaso M., Peltzer K. (2016). Change in health-related quality of life among pulmonary tuberculosis patients at primary health care settings in south Africa: A prospective cohort study. PloS one 11, e0151892. 10.1371/journal.pone.0151892 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Magis-Escurra C., Tiberi S., Akkerman O., Duarte R. (2021). Tuberculosis patients. Support. Tob. Cessat. 90, 181. [Google Scholar]
- Malik M., Nasir R., Hussain A. (2018). Health related quality of life among TB patients: Question mark on performance of TB DOTS in Pakistan. J. Trop. Med., 2018, 2538532, 10.1155/2018/2538532 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mishra A., Krishna G. S., Sravani A., Kurian T. D., Kurian J., Ramesh M., et al. (2017). Impact of pharmacist-led collaborative patient education on medication adherence and quality of life of schizophrenia patients in a tertiary care setting. Bull. Fac. Pharm. Cairo Univ. 55, 345–349. 10.1016/j.bfopcu.2017.08.001 [DOI] [Google Scholar]
- Munsour E. E., Awaisu A., Hassali M. A. A., Dabbous Z., Zahran N., Abdoun E. (2020). Impact of customized-consumer medication information on health-related quality of life among patients with type 2 diabetes mellitus. Res. Soc. Adm. Pharm. 16, 793–799. 10.1016/j.sapharm.2019.08.038 [DOI] [PubMed] [Google Scholar]
- Naqvi A. A., Hassali M. A., Naqvi S. B. S., Aftab M. T., Zehra F., Nadir M. N., et al. (2019). Assessment of patient satisfaction following pharmacist counselling session by a novel patient satisfaction feedback on counselling questionnaire. J. Pharm. Health Serv. Res. 10, 243–254. 10.1111/jphs.12294 [DOI] [Google Scholar]
- Organization W. H. (2014). Towards tuberculosis elimination: An action framework in low-incidence countries. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Organization W. H. (2021). WHO global lists of high burden countries for tuberculosis (TB), TB/HIV and multidrug/rifampicin-resistant TB (MDR/RR-TB), 2021–2025: Background document. [Online]. Available at: https://apps.who.int/iris/bitstream/handle/10665/341980/9789240029439 (Accessed March 20, 2022). [Google Scholar]
- Organization W. H. (2016). WHO treatment guidelines for drug-resistant tuberculosis [Online]. Geneva, Switzerland: World Health Organization; (Accessed Feburuary 2, 2022). [Google Scholar]
- Petersen E., Al-Abri S., Chakaya J., Goletti D., Parolina L., Wejse C., et al. (2022). World TB Day 2022: Revamping and reshaping global TB control programs by advancing lessons learnt from the COVID-19 pandemic. Int. J. Infect. Dis. 124, S1–S3. 10.1016/j.ijid.2022.02.057 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pinto S., Fumincelli L., Mazzo A., Caldeira S., Martins J. C. (2017). Comfort, well-being and quality of life: Discussion of the differences and similarities among the concepts. Porto Biomed. J. 2, 6–12. 10.1016/j.pbj.2016.11.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Qiu L., Tong Y., Yang Q., Sun N., Gong Y., Yin X. (2020). Reliability and validity of a smart quality of life scale for patients with tuberculosis. J. Public Health 28, 575–582. 10.1007/s10389-019-01067-3 [DOI] [Google Scholar]
- Saleem S., A Malik A., Ghulam A., Ahmed J., Hussain H. (2018). Health-related quality of life among pulmonary tuberculosis patients in Pakistan. Qual. Life Res. 27, 3137–3143. 10.1007/s11136-018-1954-9 [DOI] [PubMed] [Google Scholar]
- Samuel R., Natesan S., Bangera M. K. (2022). Quality of life and associating factors in pulmonary tuberculosis patients. Indian J. Tuberc. 70, 214–221. 10.1016/j.ijtb.2022.05.005 [DOI] [PubMed] [Google Scholar]
- Sartika I., Insani W. N., Abdulah R. (2019). Assessment of health-related quality of life among tuberculosis patients in a public primary care facility in Indonesia. J. Glob. Infect. Dis. 11, 102–106. 10.4103/jgid.jgid_136_18 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Saxena S., Carlson D., Billington R., Orley J. (2001). The WHO quality of life assessment instrument (WHOQOL-bref): The importance of its items for cross-cultural research. Qual. life Res. 10, 711–721. 10.1023/a:1013867826835 [DOI] [PubMed] [Google Scholar]
- Shahid F., Ismail M., Khan S. (2018). Assessment of quality of life in post burn survivors: A cross-sectional single-center first validation study from Pakistan. Burns open 2, 35–42. 10.1016/j.burnso.2017.08.003 [DOI] [Google Scholar]
- Singh S. K., Agrawal A., Tiwari K. K. (2017). Improvement in quality of life in pulmonary tuberculosis patients: A prospective study. Trop. Dr. 47, 97–100. 10.1177/0049475516643256 [DOI] [PubMed] [Google Scholar]
- Sulehri M. A., Dogar I. A., Sohail H., Mehdi Z., Azam M., Niaz O., et al. (2010). Prevalence of depression among tuberculosis patients. Ann. Punjab Med. Coll. (APMC) 4, 133–137. [Google Scholar]
- Van Hout B., Janssen M., Feng Y.-S., Kohlmann T., Busschbach J., Golicki D., et al. (2012). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value health 15, 708–715. 10.1016/j.jval.2012.02.008 [DOI] [PubMed] [Google Scholar]
- Vecino M., Pasipanodya J. G., Slocum P., Bae S., Munguia G., Miller T., et al. (2011). Evidence for chronic lung impairment in patients treated for pulmonary tuberculosis. J. Infect. public health 4, 244–252. 10.1016/j.jiph.2011.08.005 [DOI] [PubMed] [Google Scholar]
- Who G. 2020. Global tuberculosis report 2020 [Online]. Available at: https://apps.who.int/iris/bitstream/handle/10665 [Accessed 1 Janurary 2022].
- Wu P.-S., Chou P., Chang N.-T., Sun W.-J., Kuo H.-S. (2009). Assessment of changes in knowledge and stigmatization following tuberculosis training workshops in Taiwan. J. Formos. Med. Assoc. 108, 377–385. 10.1016/S0929-6646(09)60081-4 [DOI] [PubMed] [Google Scholar]
- Yuen C. M., Millones A. K., Galea J. T., Puma D., Jimenez J., Lecca L., et al. (2021). Toward patient-centered tuberculosis preventive treatment: Preferences for regimens and formulations in Lima, Peru. BMC Public Health 21, 121–128. 10.1186/s12889-020-10098-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zarova C., Chiwaridzo M., Tadyanemhandu C., Machando D., Dambi J. M. (2018). The impact of social support on the health-related quality of life of adult patients with tuberculosis in harare, Zimbabwe: A cross-sectional survey. BMC Res. notes 11, 795–797. 10.1186/s13104-018-3904-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.